Financial Comparison
AbbVie Inc. vs ELI Lilly And Company
Click a ticker to view the full analysis.
In short
ELI Lilly And Company is the more profitable of the two, keeping 31.7% of revenue as net profit against 6.9% for AbbVie Inc. AbbVie Inc. trades at the higher trailing P/E (77.0× vs 39.9× for ELI Lilly And Company), so investors pay more for each dollar of its earnings. Fisclear flags 1 medium- or high-severity risk for AbbVie Inc. and 0 for ELI Lilly And Company.
Based on filings for periods ending 30 Jun 2026 (ABBV) and 30 Jun 2026 (LLY) · Updated
FisclearScore Comparison
FisclearScore is a quantitative model. ABBV shown solid · LLY shown dashed. Not financial advice.
| Metric | ABBV | LLY |
|---|---|---|
| Price | $272.42 | $1,169.60 |
| Market Cap | $481.4B | $1.04T |
| P/E (TTM) | 77.0x | 39.9x |
| P/B | — | 30.8x |
| Beta | 0.23 | 0.45 |
| Div Yield | 2.46% | 0.59% |
| Revenue (TTM) | $61.2B | $65.2B |
| Net Income | $4.2B | $20.6B |
| Gross Margin | — | — |
| Risk Flags | 2 flags | — |
Related comparisons
Data sourced from SEC EDGAR, Yahoo Finance, and official exchange filings. For informational purposes only. Not financial advice.